gemcitabine has been researched along with Precancerous Conditions in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamada, S; Masamune, A; Shimosegawa, T; Taguchi, K; Yamamoto, M | 1 |
| Arlt, A; Deisinger, F; Helm, O; Hesse, L; Kha, ML; Röcken, C; Schäfer, H; Sebens, S; Sipos, B | 1 |
| Bendaoud, S; de Mestier, L; Hammel, P; Hentic, O; Lekhal, C; Neuzillet, C | 1 |
| Favaudon, V; Fernet, M; Huguet, F; Monnier, L; Touboul, E | 1 |
2 review(s) available for gemcitabine and Precancerous Conditions
| Article | Year |
|---|---|
[Pancreatic adenocarcinoma: 10 years of progress].
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Paclitaxel; Pancreatic Neoplasms; Precancerous Conditions | 2015 |
[New perspectives for radiosensitization in pancreatic carcinoma: a review of mechanisms involved in pancreatic tumorigenesis].
Topics: Antimetabolites, Antineoplastic; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Cystadenoma, Mucinous; Delayed Diagnosis; Deoxycytidine; Disease Progression; Gemcitabine; Genes, Tumor Suppressor; Humans; Intercellular Signaling Peptides and Proteins; Mutation; Neoplasm Proteins; Oncogenes; Pancreatic Neoplasms; Precancerous Conditions; Radiation Tolerance; Signal Transduction | 2011 |
2 other study(ies) available for gemcitabine and Precancerous Conditions
| Article | Year |
|---|---|
Nrf2 promotes mutant K-ras/p53-driven pancreatic carcinogenesis.
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Genes, p53; Male; Mice; Mutation; NF-E2-Related Factor 2; Oxidative Stress; Pancreatic Neoplasms; Precancerous Conditions; Proto-Oncogene Proteins p21(ras) | 2017 |
The antioxidant transcription factor Nrf2 modulates the stress response and phenotype of malignant as well as premalignant pancreatic ductal epithelial cells by inducing expression of the ATF3 splicing variant ΔZip2.
Topics: Activating Transcription Factor 3; Adenocarcinoma; Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Epithelial Cells; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; NF-E2-Related Factor 2; Pancreatic Ducts; Precancerous Conditions; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays | 2019 |